Trial Profile
Evaluation of 18F-AV-1451 kinetic modeling in patients in Alzheimer's disease and healthy controls
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics; Registrational
- Sponsors Avid Radiopharmaceuticals
- 06 Apr 2022 Status changed from recruiting to completed.
- 15 Sep 2015 New trial record